U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT06942143) titled 'An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors' on March 25.
Brief Summary: This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.
Study Start Date: April 23
Study Type: INTERVENTIONAL
Condition:
Sarcoma
Lung Cancers
Melanoma
Intervention:
BIOLOGICAL: Super1 TCR-T
All participators received lymphoid-depleted preconditioning before Super1 TCR-T cells infusion. Super1 TCR-T cells were infused 3 days later. Concomitant administration of interleukin for 7 consecutive days.
Recruitme...